Kornimate/medical-research-clean huggingface dataset:
determinants of post-exercise eating patterns

Conditions: Obesity

Summary: this study examines potential physiological and psychological determinants of food intake in response to exercise. specifically, beyond measuring actual food consumption and physiological markers typically assessed during exercise and appetite work (i.e. appetite hormones, blood glucose), the investigators wish to investigate the influence of individual behavioural differences (attitudes towards eating, licensing/compensatory health beliefs, self-regulation, and exercise-associated motivation) on the relationship between exercise and eating behaviour.


Eligibility criteria:
inclusion criteria: * male * inactive (\< 90 min of moderate-intensity exercise a week) * bmi: 23 and above * age between 21 to 40 years * normal fasting blood glucose levels equal to or less than 5.9 mmol/l * non-smoker * no know allergies or intolerance to food * not on any prescribed medication * no physical disabilities and/or restrictions; not averse to exercising on a stationary bike or treadmill running * no aversion to blood sampling procedures (e.g. finger prick, cannulation) exclusion criteria: * female, * smoker, * fasting blood glucose \> 5.9 mmol/l, * resting blood pressure \> 140/90 mmhg, * any major medical/health conditions including * diabetes, * metabolic disease * hypertension, * cardiovascular disease, * thyroid disorders, * g6pd deficiency. * allergic or intolerant to foods presented in the study. * physical disabilities and/or restrictions. * individuals that are adverse to exercising on a stationary exercise bike or treadmill. * adverse to blood sampling procedures (i.e. cannulation, finger pricks, venepuncture).

Keywords: appetite regulation eating behaviour exercise hiit
impact of sphb monitoring on transfusion

Conditions: Anemia

Summary: continuous and noninvasive hemoglobin (sphb) monitoring provides clinicians with real-time trending of changes or lack of changes in hemoglobin, which has the potential to alter red blood cell (rbc) transfusion decision making. the objective of this study was to evaluate the impact of sphb monitoring on rbc transfusions in high blood loss surgery. the investigators hypothesize that sphb will improve blood transfusion practice in the for of change the number of blood unit per patient and improve the outcome regards the time to take decision of transfusion trigger.

eligible patients scheduled for neurosurgeries were enrolled into either a standard care group (control group) or an intervention group (sphb group). the control group received typical anesthesia care including estimated blood loss (ebl) assessment and intraoperative hemoglobin measurements from the central laboratory (hb). blood samples were taken when ebl was ≥15% of total blood volume. rbc transfusion was initiated if hb was ≤10 g/dl and continued until the ebl was replaced and hb \>10g/dl was confirmed. the sphb group followed the same transfusion practice as the control group except the anesthesiologist was guided by the addition of sphb monitoring with blood samples still taken pre- and post-transfusion. additionally, the absolute and trend accuracy of sphb compared to hb was evaluated. potential cost savings from reduced rbc utilization will be calculated if occured.

Eligibility criteria:
inclusion criteria: * asa 1,2 patients from 15 to 60 years old scheduled for neurosurgical procedure exclusion criteria: * exclusion criteria included significant liver or renal disease, coagulopathy, pregnancy, anemia, and patients scheduled for procedures with excepted low blood loss.

Keywords: anemia blood transfusion non invasive hemoglobin monitoring patient safety
comparison of two new silicone hydrogel multifocal products

Conditions: Presbyopia

Summary: the purpose of this trial is to compare the performance of two multifocal contact lenses.


Eligibility criteria:
inclusion criteria: * at least 35 years of age * best-corrected visual acuity of at least 20/40 in each eye. * spectacle add between +0.75d and +1.50d (inclusive). * able to be fit in available study sphere powers (-0.50 to -5.50d). * currently wearing soft contact lenses at least 5 days a week. * other protocol inclusion/exclusion criteria may apply. exclusion criteria: * requires concurrent ocular medication. * eye injury or surgery within twelve weeks immediately prior to enrollment. * currently enrolled in an ophthalmic clinical trial. * evidence of systemic or ocular abnormality, infection or disease likely to affect successful wear of contact lenses or use of their accessory solutions. * previous refractive surgery. * astigmatism \> 1.00d. * currently wearing acuvue oasys for presbyopia. * other protocol inclusion/exclusion criteria may apply.
a research study looking at how oral semaglutide works in people with type 2 diabetes in italy, as part of local clinical practice

Conditions: Diabetes Mellitus, Type 2

Summary: the purpose of the study is to collect information on how rybelsus® works in people with type 2 diabetes and to see if rybelsus® can lower their blood sugar levels. participants will get rybelsus® as prescribed to them by the study doctor. the study will last for about 8-10 months. participants will be asked to complete a questionnaire about how they take their rybelsus® tablets. participants will complete this questionnaire during their normally scheduled visit with the study doctor.


Eligibility criteria:
inclusion criteria: 1. signed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol) 2. diagnosed with type 2 diabetes mellitus 3. the decision to initiate treatment with commercially available oral semaglutide has been made by the patient/legally acceptable representative (lar) and the specialist based on local label before and independently from the decision to include the patient in this study 4. male or female, age above or equal to 18 years at the time of signing informed consent 5. available hba1c value below or equal to 90 days prior to the 'informed consent and treatment initiation visit' (v1) or hba1c measurement taken in relation with the 'informed consent and treatment initiation visit' (v1) if in line with local clinical practice 6. treatment naïve to injectable glucose-lowering drug(s). an exception is short-term insulin treatment for acute illness for a total of below 14 days exclusion criteria: 1. previous participation in this study. participation is defined as having given informed consent in this study 2. treatment with any investigational drug within 30 days prior to enrolment into the study 3. mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
successful pregnancy and delivery after aoa

Conditions: Infertility

Summary: artificial oocyte activation with strontium chloride or calcium ionophore improves fertilization, embryo quality, pregnancy and delivery rate in women who showed complete fertilization failure or low fertilization rates


Eligibility criteria:
inclusion criteria: * fertilization rate was less than 30% after conventional icsi. * fertilization rate was less than 50% after icsi with calcium ionophore. * repeated complete fertilization failure or low fertilization rates following icsi in previous cycles exclusion criteria: * fertilization rate was more than 30% after conventional icsi * fertilization rate was more than 50% after icsi with calcium ionophore. * successful pregnancy and delivery after icsi in previous cycles

Keywords: fertilization failure, calcium ionophore, srcl2
phase 1 study evaluating safety and tolerability of sl-t10, gx-i7, and pembrolizumab triple combination in mcrpc.

Conditions: Metastatic Castration-resistant Prostate Cancer (mCRPC)

Summary: the purpose of this study is to evaluate the efficacy and safety of sl-t10 and gx-i7 or sl-t10, gx-i7 and pembrolizumab in patients with metastatic castration-resistant prostate cancer (mcrpc).

the purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of sl-t10, gx-i7, and pembrolizumab in combination in patients with metastatic castration-resistant prostate cancer (mcrpc).

Eligibility criteria:
inclusion criteria: 1. male patients 19 years of age or older at the date of written informed consent. 2. patients with histopathologically or cytologically confirmed adenocarcinoma of the prostate, documented by bone or soft tissue lesions. 3. patients with castration-resistant prostate cancer with a blood testosterone level of less than 50 ng/dl at the screening visit. 4. patients with metastatic castration-resistant prostate cancer (mcrpc) who meet the following criteria (based on pcwg3.0 modified recist 1.1) 1) prior taxane therapy for metastatic prostate cancer or confirmed refusal or inadequacy of such therapy 2) patients who have received prior docetaxel and at least one of the following agents: abiraterone acetate or enzalutamide before or after docetaxel treatment 3) patients with progression of prostate cancer during/after prior therapy, in the investigator's judgment, with either of the following, in the internal or external castration state 1. psa progression defined as at least 2 psa level increases (≥1 week interval between each test) and a psa level of ≥2 ng/ml at screening 2. advanced soft tissue disease as defined by recist 1.1 3. progressive bone disease defined as ≥2 new lesions on bone scan (per pcwg3) 5. patients who are on androgen deprivation therapy (adt) of any kind (patients who have not undergone bilateral orchiectomy must begin internal castration therapy, such as luteinizing hormone-releasing hormone (lhrh) agonists, lhrh antagonists, or anti-androgenic agents, at least 4 weeks prior to baseline and must continue for the entire duration of the study) exclusion criteria: 1. patient has an active autoimmune disease or is receiving systemic steroid therapy or in immunosuppressive status. 2. patient has history of chemotherapy, radiation chemotherapy, biological therapy, immunotherapy, or radiation therapy within 4 weeks prior to the screening visit (in case of nitrosoureas or mitomycin, 6 weeks prior to the screening visit)
enhancing maturation of autogenous arteriovenous hemodialysis access by aggressive surveillance with duplex and endovascular treatment

Conditions: End Stage Renal Disease

Summary: the aim of this study is to evaluate whether aggressive duplex surveillance after vascular access surgery with native vein for hemodialysis can increase the maturation rate of arteriovenous fistula. this study will be conducted as a single center, prospective, 1:1 randomized study. enrolled patients will be randomized as a control group (physical exam at 2 and 4 weeks after surgery) and duplex group (duplex study and physical exam at 2 and 4 weeks after surgery). maturation of arteriovenous fistula will be evaluated at 8 weeks after surgery by duplex in all patients.


Eligibility criteria:
inclusion criteria: * end stage renal disease * newly formed hemodialysis access with native vein * 20\~70 years exclusion criteria: * hemodialysis access surgery with eptfe graft * hemodialysis access surgery with basilic vein transposition * hemodialysis access surgery with brachial vein transposition * cephalic vein \< 2.5mm in diameter * radial artery diameter \<2.0mm in radiocephalic arteriovenous fistula

Keywords: duplex study hemodialysis access maturation rate endovascular intervention
concomitant hybrid versus catheter ablation for atrial fibrillation with hypertrophic cardiomyopathy

Conditions: Atrial Fibrillation; Cardiomyopathy, Hypertrophic; Radiofrequency Ablation

Summary: the goal of this clinical trial is to compare the rhythm control effect in hypertrophic non-obstructive patients with non-paroxysmal atrial fibrillation by either concomitant catheter endocardial and thoracoscopic epicardial ablation or catheter ablation alone. the study aims to see if concomitant hybrid ablation can more effectively achieve rhythm control effect than catheter ablation alone in non-paroxysmal atrial fibrillation patients with hypertrophic cardiomyopathy.

after informed consent, 66 eligible admissions will be recruited in 2 centers. eligible participants will be randomly divided (1:1) into either hybrid or catheter ablation arms, looking for a primary outcome of 1-year freedom from atrial arrhythmias.

Eligibility criteria:
inclusion criteria: 1. patients' age is ≥18 y 2. clinically diagnosed hypertrophic cardiomyopathy (any left ventricular wall segment thickness ≥15 mm in genetical negative (or unknown genetical status) patients or ≥13mm in genetical positive ones-as measured by any imaging technique (echocardiography, cardiac magnetic resonance imaging or computed tomography)-that is not explained solely by loading conditions) 3. non-obstructed left ventricular outflow obstruction with peak gradients \<30mmhg 4. concomitant with persistent atrial fibrillation (7 days\<sustained episode lasting\<3 years) with drug-refractory symptoms. 5. be able to understand the contents of the trial, and provide written informed consent to participate in this investigation. exclusion criteria: 1. patients with left atrial size \>60 mm (2-dimensional echocardiography, parasternal long-axis view) 2. contraindicated to systemic anticoagulation 3. left ventricular ejection fraction ≤40% 4. concomitant with left atrium or left atrial appendage emboli 5. concomitant with a coronary or valvular disease that indicates intervention 6. ischaemic stroke within 2 months 7. previous ablation history 8. uncontrolled hyper/hypothyroidism 9. end-staged kidney failure 10. concomitantly involved in other trials 11. pregnant or breastfeeding, or women of childbearing age not using a reliable contraceptive method 12. concomitant with bacteremia or at an active phase of infection 13. anatomically not suitable for thoracoscopic surgery(history of chest surgery or radiotherapy, etc.) 14. unwilling or unable to comply with all peri-ablation and follow-up requirements
nystagmus assessment for patients consulting in the emergency department for acute vertigo

Conditions: Nystagmus, Acquired; Stroke, Acute

Summary: this pilot study is perfomed to validate and document faisability of the use of frenzel lens and the use of a diagnostic algorithm for the assessment of a special sign (nystagmus) observe in the eyes of patients consulting in the emergency department (ed) for an acute episode of vertigo/dizziness/imbalance.

this pilot study is a randomized controlled trial 2 by 2 design to allocated randomly the frenzel lens and the diagnostic algorithm. there is no use of sham lens. the usual care opposed to the diagnostic algorithm will be questioned only on the perception of nystagmus by the clinician and the use of repositioning particles technique. the only blinding will be the patients about the use of the algorithm and the outcomes assessor about the use or not of frenzel lens and the use or not of the diagnostic algorithm.

Eligibility criteria:
inclusion criteria: * new episode of acute vertigo/dizziness/imbalance occuring during the 28 last days * must be able to consent. exclusion criteria: * no traumatic context before symptoms onset * no intoxication context * glycemia ≤ 3,0 mmol/l * only one participation is permitted * not able to speak adequately in french or english. * reachable for 3 month follow-up

Keywords: nystagmus stroke neuroimaging cardiovascular disease benign positional paroxystic vertigo
randomized trial of acetazolamide for uveitis-associated cystoid macular edema

Conditions: Macular Edema, Cystoid

Summary: to test the efficacy of acetazolamide for the treatment of uveitis-associated cystoid macular edema.

uveitis, an intraocular inflammatory disease, is the cause of about 10 percent of visual impairment in the united states. uveitis may lead to many sight-threatening conditions, including cataract, vitreal opacities, glaucoma, and, most commonly, cystoid macular edema. reduction of swelling or edema within the retina depends on the movement of fluid from the retina through the choroid. a number of studies indicate that this process requires active transport of fluid ions by the retinal pigment epithelium and may involve the carbonic anhydrase system. current treatment of uveitis-associated cystoid macular edema requires the use of immunosuppressive or anti-inflammatory agents. however, many patients are either resistant or intolerant to this therapy. recent reports suggested that acetazolamide, a carbonic anhydrase inhibitor that is used to lower intraocular pressure in some glaucoma patients, might be safe and effective in reducing uveitis-associated cystoid macular edema. because the course of ocular inflammatory disease can be variable, a double-masked, randomized, crossover trial was designed to test the efficacy of acetazolamide compared with a placebo for the treatment of uveitis-associated cystoid macular edema. randomized adult patients received either oral acetazolamide sodium 500 mg or a matched placebo every 12 hours for the first 4 weeks of the study. children 8 years of age or older received a lesser dose based on body weight. following a 4-week period, during which no medication was given, patients then received a 4-week course of the opposite medication. primary end points included reduction in cystoid macular edema (graded on fluorescein angiography) and improvement in visual acuity (measured on standardized early treatment diabetic retinopathy study \[etdrs\] charts). laser acuity was also assessed as a secondary outcome variable. adverse effects of the acetazolamide therapy were monitored by clinical and laboratory examinations. a total of 40 patients were recruited for the study. patients were seen at the beginning of the study for baseline measurements and at 4, 8, and 12 weeks after enrollment into the study.

Eligibility criteria:
males and females 8 years of age or older and weighing at least 35 kg (77 lb) were eligible for the study. patients had to have a best corrected visual acuity of 20/40 or worse in at least one eye with cystoid macular edema demonstrable on fluorescein angiography. patients were allowed to receive systemic therapy for their uveitis. exclusion criteria included current use of acetazolamide as part of a therapeutic regimen; a history of hypersensitivity reactions to acetazolamide, sulfonamides, or angiography dye; unclear ocular media that would obscure fluorescein angiography; macular subretinal neovascularization or a macular hole; or inability to take acetazolamide for medical reasons.
cognitive remediation in alcohol disorders

Conditions: Alcohol Disorders

Summary: the individual and societal cost of alcohol use disorders (tual), present in 10% of the population in france, is considerable. despite psychotherapeutic and drug addiction treatment, the relapse rate remains very high, partly because of their very frequent cognitive disorders. in fact, more than 75% of tual patients present to varying degrees neuropsychological alterations that are only rarely detected and never treated. however, these cognitive disorders limit the benefit of psychotherapeutic care, reduce compliance with pharmacological treatments and hinder the patient's ability to change his behavior with respect to alcohol. an innovative way to promote the maintenance of the therapeutic contract, and therefore to reduce alcohol consumption in these patients, would be to improve their cognitive functioning. the objective of this study is to measure the efficacy of a non-drug treatment, based on a specific and personalized cognitive remediation program, compared to a standard treatment in day hospitalization, in order to reduce the rate of relapse very high in tual. it is a randomized, single-blind study with two parallel groups of patients with post-weaning neuropsychological disorders: remed (cognitive remediation) and control (usual care).


Eligibility criteria:
inclusion criteria: * patient male or female aged 18 to 60, french speaking and affiliated to the social security system * patient with tual (dsm-5) at the forefront of alcohol use disorders at the time of inclusion * patient with neuropsychological disorders objectified on bearni (bearni for brief evaluation of alcohol-related neuropsychological evaluation, ritz et al., 2015 cut-off cognitive score = 13, adding a point for patients with bachelor level or lower) and confirmed at the neuropsychological checkup showing pathological performance (at least two free or total recalls of rl / ri 16 \<-1.65 and / or rbmt igm \<-1.65 or number of persecutory or deficit errors at mcst \<-1.65 and / or at least two bads subtests with a score of \<or = 2 (except temporal judgment)). evaluation (bearni) at least 48h after stopping benzodiazepines * patient weaned of alcohol, that is to say between 5 and 21 days after stopping alcohol, after disappearing signs of withdrawal (cushman score \<2) and stopping benzodiazepines * first hospitalization type day hospital (not necessarily first weaning) * patient having been informed of the study and being able to give written informed consent. exclusion criteria: * patient with severe and long-lasting neurological complications related to alcohol (korsakoff syndrome, fetal alcohol syndrome, ...) * patient with a disorder of severe use of another psychoactive substance according to dsm-5, except tobacco * patient with motor or sensory deficit making cognitive remediation impossible * patient previously included or already included in another biomedical research * homeless patient
dry eye outcome and prescription study

Conditions: Dry Eye; Dry Eye Syndrome; Blepharitis; Meibomian Gland Dysfunction; Eye Pain; Punctate Epithelial Keratitis; Punctate Keratitis; Tear Film Insufficiency; Kerato Conjunctivitis Sicca; Eye Diseases

Summary: the dry eye outcome and prescription study (drops) is a large observational multicentre study exploring the 'real world' effectiveness of artificial tears in dry eye disease and determinants of efficacy. the aim is to include at least 635 symptomatic dry eye patients who are prescribed artificial tears. all trainees and fellows in london are invited to become collaborators: collaborators are asked to consent patients, assess signs at baseline, and give patients questionnaires at baseline and 4 weeks (for home completion). in tandem, we are conducting a qualitative review of ophthalmologists' prescribing behaviours for dry eye disease.


Eligibility criteria:
inclusion criteria: * adult patients (18 years and over) with symptoms\* of dry eye disease (with or without signs, with or without blepharitis) who start one or more artificial tears. \*symptoms of dry eye disease include: foreign body sensation, dryness, irritation, itching, burning, stinging or grittiness. when signs are present, symptoms of visual disturbance such as poor vision and blurred vision are sufficient as a symptom of dry eye disease too * must have best corrected visual acuity in at least one eye of at least 6/12. exclusion criteria: * lacks capacity (e.g. dementia) * poor understanding of english * active other apparent ocular surface disease (including conjunctivitis, abrasion, recurrent erosion syndrome, episcleritis, inflamed pingueculum or pterygium, tumour, infectious keratitis). * immune ocular pathology (including scleritis and uveitis). * recent (within the last 3 months) or planned ocular surgery or intravitreal injections. * current use of other ocular medication, e.g. antiglaucoma drops, g ciclosporine. * use of artificial tears or ointment in the last 1 month. * gross lid abnormalities, including significant ectropion or entropion; facial nerve palsy; thyroid eye disease; trichiasis. for the qualitative interview study: subject inclusion criteria - london nhs consultant with at least 6 months experience as a consultant, with a special interest in cornea and external diseases, accident and emergency and primary care, or general ophthalmology